We have located links that may give you full text access.
Visual Performance, Subjective Satisfaction and Quality of Life Effect of a New Refractive Intraocular Lens with Central Extended Depth of Focus.
Klinische Monatsblätter Für Augenheilkunde 2019 April
PURPOSE: To assess the visual performance, clinical and quality of life outcomes, and subjective patient satisfaction after implantation of a new refractive/extended depth of focus (EDOF) hybrid intraocular lens (IOL).
METHODS: This is a monocentric, retrospective study of 29 patients (45 eyes), carried out in a tertiary care glaucoma research centre. All patients underwent implantation of a Lucidis (Swiss Advanced Vision, SAV-IOL SA, Neuchâtel, Switzerland) IOL during cataract surgery. Near, intermediate, and distance best-corrected visual acuities and uncorrected visual acuities were collected at baseline and 3 months postoperatively. Adverse events, contrast sensitivity, optical aberrations, subjective satisfaction, and spectacle independence were also analysed at 3 months.
RESULTS: At 3 months postoperatively, the mean photopic uncorrected monocular distance, and intermediate and near visual acuities were 0.2 logMAR (~ 20/32), 0.07 logMAR (~ 20/23), and 0.15 logMAR (~ 20/28), respectively. Mean best-corrected visual acuity was 0.05 logMAR (~ 20/23) for distance and 0.03 logMAR (~ 20/21) for near vision. Mean photopic contrast sensitivity was 1.5 log. The mean root mean square (RMS) was 0.119 ± 0.05 µm. Subjectively, over the 3-month follow-up, 9% of patients (n = 4) complained of halos, and 2% (n = 1) of photophobia. No other adverse events were noted.
CONCLUSIONS: The Lucidis IOL demonstrates a good safety profile, with an acceptably low complication rate. While the uncorrected visual performance of this new optical design is inferior to that of other EDOF IOLs for distance vision, it achieves better results in intermediate and near vision, with consistently near-normal contrast sensitivity. Interestingly, self-reported spectacle independence and subjective patient satisfaction were high for all distances.
METHODS: This is a monocentric, retrospective study of 29 patients (45 eyes), carried out in a tertiary care glaucoma research centre. All patients underwent implantation of a Lucidis (Swiss Advanced Vision, SAV-IOL SA, Neuchâtel, Switzerland) IOL during cataract surgery. Near, intermediate, and distance best-corrected visual acuities and uncorrected visual acuities were collected at baseline and 3 months postoperatively. Adverse events, contrast sensitivity, optical aberrations, subjective satisfaction, and spectacle independence were also analysed at 3 months.
RESULTS: At 3 months postoperatively, the mean photopic uncorrected monocular distance, and intermediate and near visual acuities were 0.2 logMAR (~ 20/32), 0.07 logMAR (~ 20/23), and 0.15 logMAR (~ 20/28), respectively. Mean best-corrected visual acuity was 0.05 logMAR (~ 20/23) for distance and 0.03 logMAR (~ 20/21) for near vision. Mean photopic contrast sensitivity was 1.5 log. The mean root mean square (RMS) was 0.119 ± 0.05 µm. Subjectively, over the 3-month follow-up, 9% of patients (n = 4) complained of halos, and 2% (n = 1) of photophobia. No other adverse events were noted.
CONCLUSIONS: The Lucidis IOL demonstrates a good safety profile, with an acceptably low complication rate. While the uncorrected visual performance of this new optical design is inferior to that of other EDOF IOLs for distance vision, it achieves better results in intermediate and near vision, with consistently near-normal contrast sensitivity. Interestingly, self-reported spectacle independence and subjective patient satisfaction were high for all distances.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app